Wikipedia

Urotensin-II receptor

The urotensin-2 receptor (UR-II-R) also known as GPR14 is a class A rhodopsin family G protein coupled-receptor (GPCR) that is 386 amino acids long which binds primarily to the neuropeptide urotensin II.[1] The receptor quickly rose to prominence when it was found that when activated by urotensin II it induced the most potent vasoconstriction effect ever seen.[5] While the precise function of the urotensin II receptor is not fully known it has been linked to cardiovascular effects, stress, and REM sleep.

UTS2R
Identifiers
AliasesUTS2R, GPR14, UR-2-R, UTR, UTR2, urotensin 2 receptor
External IDsOMIM: 600896; MGI: 2183450; HomoloGene: 10345; GeneCards: UTS2R; OMA:UTS2R - orthologs
Orthologs
SpeciesHumanMouse
Entrez

2837

217369

Ensembl

ENSG00000181408

ENSMUSG00000039321

UniProt

Q9UKP6

Q8VIH9

RefSeq (mRNA)

NM_018949
NM_001381897

NM_145440

RefSeq (protein)

NP_061822
NP_001368826

NP_663415

Location (UCSC)Chr 17: 82.37 – 82.38 MbChr 11: 121.05 – 121.05 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Ligands

edit

There are two known endogenous agonists for the urotensin II receptor. One is urotensin II whose mRNA is found in a variety of tissues including the brain and also blood vessels. It is a potent vasoconstrictor and can increase REM cycles. The other is urotensin II-Related Peptide (URP) which is found in a variety of tissues as well although at less concentrations then urotensin II. The one exception is in human reproductive tissue where the levels of URP are much higher than urotensin II.

Cellular Pathway

edit
 
Activation protein kinase C

Urotensin II Receptor interacts with the G Protein whose alpha subunit is Gαq11 which is mainly involved in activating Protein Kinase C (PKC). This then activates phospholipase C which increases the intercellular amount of calcium through the activation of IP3 which is an intracellular molecule that acts as secondary messenger. IP3 will then release calcium which then activates PKC.

When the urotensin II receptor is activated it also promotes beta arrestin translocation. Beta arrestin is important for ceasing the response of a receptor to a stimuli. Beta arrestin also brings with it other proteins that internalize the receptor which also helps in desensitizing the cell to the stimuli.[6]

Tissue distribution

edit

Based on RT-PCR techniques the urotensin II receptor appears to be expressed throughout the entire brain.[7] On the other hand, when using in situ hybridization technique which is less sensitive but provides more information of the anatomical location urotensin II receptor mRNA was shown to be restricted to the brainstem cholinergic neurons of the laterodorsal tegmental (LDT) and the pedunculopontine tegmental nuclei (PPT) both of which are important for REM sleep.[8] These two different results are because urotensin II receptor can also be found in blood vessels which is what the sensitive RT-PCR technique was likely detecting. Urotensin II receptors are also found in the cholinergic neurons of the spinal cord indicating some type of motor function.

Urotensin II receptors have also been found in other peripheral tissues and blood vessels. This suggests some effects on the cardiovascular system.

Function

edit

CNS

edit

When the urotensin II receptor is activated through an intracerebroventricular (icv) injection of urotensin II it causes an increase of corticotropin releasing factor through the activation of the hypothalamic paraventricular neurons (PVN) which lead to increased plasma levels of adrenocorticotropic hormones. C-fos levels which go up whenever there is an increase in neural activity were detected in the brain 20 minutes after the urotensin II was injected. The stimulation of the PVN by the activation of urotensin II receptor means that it directly affects the hypothalamus pituitary axis (HPA) which is important in the regulation of many important body functions.[9] Rats also exhibit many stress related behaviors when injected with urotensin II such as pacing and fidgeting in familiar environments.

REM sleep is controlled by the cholinergic neurons in the PPT and LDT. Local injection of urotensin II into the PPT to leads to increased REM sleep episodes where the firing of the cholinergic neurons was observed through electrophysiological studies. The studies also showed there was no effect on the non-cholinergic neurons. Wakefulness and slow wave sleep were not affected by the activation of the urotensin II receptor.[10]

Cardiovascular

edit

Short term effects of the activation of the urotensin II receptor is the burst intercellular calcium in the aorta which causes vasoconstriction of the vessel. There is also evidence that there are long term effects of the activation of the urotensin II receptor which could play a role in cardiomyocytic hypertrophy.[11]

Gene

edit

Human urotensin II receptor is located on chromosome 17q25 as an intronless gene. There are no known subtypes of the receptor but the possibility cannot be discounted. It has similar domain sequences to the somatostatin receptor, and in lab conditions can be activated by somatostatin.[12]

Clinical significance

edit

Mutations

edit

There is one single-nucleotide polymorphism that is known to occur in humans regarding the urotensin II receptor. R1483.50 is instead H1483.50 which effects how the cell responds when the urotensin II receptor is activated. The receptor cannot activate the PKC but it can still activate the ERK1/2 pathway although it is a little bit slower.

There have been studies done on specific amino acids on the urotensin II receptor especially the ones that are homologous to the other members of the rhodopsin family. These include, D972.50, E1473.49, and Y1493.50. In all cases the amino acids were converted to alanine and their effects were observed. The mutated D972.50 receptor could not activate PKC nor could it activate the ERK1/2 pathway. This meant that it affected the activation of both pathways and plays a critical role. The other two amino acids which were mutated E1473.49 and Y1493.50 still activated both PKC and ERK1/2 suggesting that they did not play a critical role in the activation of the pathway.[13]

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000181408 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000039321 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Müller C, Müller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P (Oct 2004). "Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System". The Journal of Pharmacology and Experimental Therapeutics. 311 (1): 204–12. doi:10.1124/jpet.104.068320. PMID 15146030. S2CID 2011410.
  6. ^ Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. (1999). "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14". Nature. 401 (6750): 282–6. Bibcode:1999Natur.401..282A. doi:10.1038/45809. PMID 10499587. S2CID 4564765.
  7. ^ Gartlon J, Parker F, Harrison DC, Douglas SA, Ashmeade TE, Riley GJ, Hughes ZA, Taylor SG, Munton RP, Hagan JJ, Hunter JA, Jones DN (2001). "Central effects of urotensin-II following ICV administration in rats". Psychopharmacology. 155 (4): 426–33. doi:10.1007/s002130100715. PMID 11441433. S2CID 22774771.
  8. ^ Clark SD, Nothacker HP, Wang Z, Saito Y, Leslie FM, Civelli O (2001). "The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat". Brain Research. 923 (1–2): 120–7. doi:10.1016/s0006-8993(01)03208-5. PMID 11743979. S2CID 29248060.
  9. ^ Watson AM, Lambert GW, Smith KJ, May CN (2003). "Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions". Hypertension. 42 (3): 373–9. doi:10.1161/01.HYP.0000084633.85427.E6. PMID 12885791.
  10. ^ Nothacker HP, Clark S (2005). "From heart to mind. The urotensin II system and its evolving neurophysiological role". The FEBS Journal. 272 (22): 5694–702. doi:10.1111/j.1742-4658.2005.04983.x. PMID 16279935. S2CID 83184639.
  11. ^ Saetrum Opgaard O, Nothacker H, Ehlert FJ, Krause DN (2000). "Human urotensin II mediates vasoconstriction via an increase in inositol phosphates". European Journal of Pharmacology. 406 (2): 265–71. doi:10.1016/s0014-2999(00)00672-5. PMID 11020490.
  12. ^ Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP, Civelli O (1999). "Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction". Nature Cell Biology. 1 (6): 383–5. doi:10.1038/14081. PMID 10559967. S2CID 41304445.
  13. ^ Proulx CD, Holleran BJ, Boucard AA, Escher E, Guillemette G, Leduc R (2008). "Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor". Molecular Pharmacology. 74 (3): 552–61. doi:10.1124/mol.108.045054. PMID 18509066. S2CID 9019351.

Further reading

edit
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Urotensin-II_receptor&oldid=1212899997"